STAT3 and B-cell non-Hodgkin lymphoma: ,31 Here, we assessed whether silencing Stat3 with CpG-Stat3 siRNA can significantly enhance the efficacies of CTLA4 antibody therapy in B cell lymphoma by augmenting the immunostimulatory effects.